Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 févr. 2022 18h17 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2022...
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
22 févr. 2022 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year...
Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
01 févr. 2022 08h00 HE
|
Sarepta Therapeutics, Inc.
Collaboration combines Sarepta’s proprietary gene editing technologies and GenEdit’s non-viral delivery platform to create new genetic medicines for patients with neuromuscular diseasesInitial results...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 janv. 2022 18h15 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022...
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
10 janv. 2022 10h50 HE
|
Sarepta Therapeutics, Inc.
Participants from the placebo crossover group in Part 2 of Study SRP-9001-102 , scored 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) 48 weeks after treatment with SRP-9001...
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
06 janv. 2022 08h32 HE
|
Sarepta Therapeutics, Inc.
Presentation on Monday, Jan. 10, 2022, to include topline results from Part 2 of Study SRP-9001-102 CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 déc. 2021 20h45 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2021...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 nov. 2021 18h17 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2021...
Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
17 nov. 2021 08h31 HE
|
Sarepta Therapeutics, Inc.
Gilmore O’Neill, M.B., M.M.Sc., will depart the Company and serve in a consulting capacity through March 31, 2022 CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....
Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
17 nov. 2021 08h30 HE
|
Sarepta Therapeutics, Inc.
A renowned expert in protein engineering, Dr. Mayo brings extensive scientific expertise and strong business acumen to the Company’s board CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) --...